Vital Signs The Analyst's Perspective - October 2016 Issue

USD 600.00

* Required Fields

USD 600.00


Be the first to review this product

This Vital Signs issue discusses the Danaher's acquisition of Cepheid for nearly $4 Billion in cash, and Orphan Drug Expenditures in the United States: A Historical and Prospective Analysis, 2007–2013.

Table of Contents

Vital Signs The Analyst's Perspective - October 2016 IssueVital Signs - October 2016 IssueOctober 2016 Issue




Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.